更新于：2024-11-04
Cernilton
舍尼通
更新于：2024-11-04
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
关联
2
项与 舍尼通 相关的临床试验Comparison of cernitin pollen extract and tadalafil in the treatment for benign prostatic hyperplasia with chronic prostatitis: A randomized, prospective study - Comparison of cernitin pollen extract and tadalafil in the treatment for chronic prostatitis
Phase 3 Study of a Standardized Pollen Extract Preparation (Cernilton) in Patients With Inflammatory Chronic Prostatitis-chronic Pelvic Pain Syndrome
100 项与 舍尼通 相关的临床结果
登录后查看更多信息
100 项与 舍尼通 相关的转化医学
登录后查看更多信息
100 项与 舍尼通 相关的专利（医药）
登录后查看更多信息
66
项与 舍尼通 相关的文献（医药）2021-02-01Wiener klinische Wochenschrift4区 · 医学
A glimpse into the efficacy of alternative therapies in the management of benign prostatic hyperplasia
4区 · 医学
Review
作者: Hossain, Md Amir ; Wazir, Junaid ; Zhou, Xiaohui ; Ihsan, Awais Ullah ; Ullah, Rahat ; Khan, Farhan Ullah ; Diallo, Maladho Tanta
Benign prostatic hyperplasia (BPH) is a common disease that can cause uncomfortable lower urinary tract symptoms. The occurrence of symptomatic BPH develops after the age of 40 years and increases gradually with age to reach more than 50% at the age of 60 years and severely disturbs the quality of life of the patients. Alpha-blockers and 5‑alpha reductase inhibitors are first-line agents used for the treatment of BPH. Due to the adverse effects of these conventional therapies, many patients turn to phytotherapy and other alternative therapies. This review covers alternative therapies, i.e., phytotherapy (cernilton, eviprostat, quercetin, saw palmetto and pumpkin seed) and physical therapy (acupuncture, aquablation, pulsed electromagnetic field, prostate urethral lift, radial extracorporeal shock wave therapy, thermobalancing therapy, and transurethral needle ablation) commonly used in the management of BPH.
2020-09-01Neurourology and urodynamics3区 · 医学
Comparison of cernitin pollen extract vs tadalafil therapy for refractory chronic prostatitis/chronic pelvic pain syndrome: A randomized, prospective study
3区 · 医学
Article
作者: Fujita, Takashi ; Ishida, Shohei ; Naito, Yushi ; Funahashi, Yasuhito ; Gotoh, Momokazu ; Tochigi, Kosuke ; Matsukawa, Yoshihisa ; Kato, Masashi
Abstract:
Aims:
To compare the efficacy of cernitin pollen extract (cernitin) or tadalafil for treating persistent chronic pelvic pain despite α1‐blocker monotherapy in men with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) and lower urinary tract symptoms (LUTS).
Methods:
A total of 100 patients with refractory CP/CPPS despite ongoing α1‐blocker monotherapy were randomized to receive add‐on therapy with either cernitin (4 capsules/day) or tadalafil (5 mg/d) for 12 weeks. At week 12, changes from baseline in the patients’ CP/CPPS, LUTS, and voiding function, as assessed using the National Institutes of Health Chronic Prostatitis Symptom Index (NIH‐CPSI), the International Prostate Symptom Score (IPSS), and uroflowmetry, respectively, were compared between the groups.
Results:
The final analysis included 42 and 45 patients in the cernitin and tadalafil groups, respectively. Although the NIH‐CPSI total, NIH‐CPSI pain sub‐score, and NIH‐CPSI quality of life sub‐score significantly improved in both groups, the cernitin (vs tadalafil) group showed significantly greater improvements in the NIH‐CPSI total score (−6.8 vs −4.6; P = .02) and NIH‐CPSI pain sub‐score (−4.1 vs −1.5; P < .001). Half (50%) of the patients in the cernitin group showed a reduction greater than 50% in their NIH‐CPSI pain sub‐score; in the tadalafil group, only four patients (8.9%) showed ≥50% improvement (P < .001). In contrast, the improvement in LUTS was significantly superior in the tadalafil group.
Conclusion:
Both cernitin and tadalafil significantly ameliorated chronic pelvic pain in patients with refractory CP/CPPS. The add‐on of cernitin was more effective than tadalafil for pelvic pain and discomfort.
2020-01-01Pharmaceutical biology3区 · 医学
The effect of Jiedu Huoxue decoction on rat model of experimental nonbacterial prostatitis via regulation of miRNAs
3区 · 医学
ArticleOA
作者: Mao, Wenli ; Wang, Jiangang ; Yi, Jun ; Yan, Zhangren ; Huang, Chunhua ; Wang, Wanchun ; Huang, Gang ; Wu, Yunbo
CONTEXT:
The underlying mechanisms of Jiedu Huoxue decoction (JDHXD) in treating chronic prostatitis have not been fully explored.
OBJECTIVE:
This study investigates the miRNAs as potential biomarkers and the effect of JDHXD on the rat model of experimental nonbacterial prostatitis.
MATERIALS AND METHODS:
Fifty-four Sprague-Dawley male rats were randomly divided into normal control, model, JDHXD low dose (0.5 g/kg/day), medium dose (1 g/kg/day), high dose (2 g/kg/day) and western medicine (cernilton 0.094 g/kg/day) groups, and intragastrically administered once daily for 30 days. The control and model (upon successful establishment) groups received distilled water. Differential expression of miRNAs was analysed with high-throughput miRNA sequencing and validated with qRT-PCR and Northern blot. Prediction of specific target genes and functional enrichment analysis were performed with bioinformatics.
RESULTS:
LD50 test showed no sign of toxicity with maximum feasible dose 4 g/kg JDHXD. Compared with control, 495 miRNAs showed expression changes in CAP/CPPS rats, of which 211 were significantly different and 37 were prostatic-related. There were 181 differentially expressed miRNAs between the model and high dose JDHXD groups, of which 23 were identical with the control and model groups. Compared with control, miR-146a, miR-423 and miR-205 expression increased significantly in the model group, decreased dose-dependently in the JDHXD groups (p < 0.05), and vice-versa for miR-96 (p < 0.05). The effect of low dose JDHXD was comparable to cernilton (p > 0.05).
DISCUSSION AND CONCLUSIONS:
Future studies may explore the contributions of the active components in JDHXD. The study design is generalisable. The effect can be repeatedly verified in clinical trials.
100 项与 舍尼通 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性前列腺炎 | 日本 | 1968-09-05 | |
| 前列腺增生症 | 日本 | 1968-09-05 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 139 | (Cernilton) | 積壓構製齋顧鹹觸廠構(醖積製鏇襯獵衊憲壓築) = 膚繭觸簾鑰築鹽窪淵醖 觸鏇憲顧簾齋網鑰選鏇 (衊網淵膚築夢齋顧廠願, 憲衊鏇壓鹹鑰憲選鏇衊 ~ 鬱積鹽衊鏇夢衊獵鏇夢) 更多 | - | 2009-06-12 | ||
Placebo (Placebo) | 積壓構製齋顧鹹觸廠構(醖積製鏇襯獵衊憲壓築) = 夢製鑰願醖鏇淵襯夢願 觸鏇憲顧簾齋網鑰選鏇 (衊網淵膚築夢齋顧廠願, 構淵鬱壓餘襯窪壓簾艱 ~ 蓋鹹鬱膚積窪獵膚繭構) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用